Linnea Chap is an Oncology physician affiliated with University of California, Los Angeles. OpenAlex indexes 44 publications with 3,238 citations (h-index 16); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8900 Wilshire Blvd
Beverly Hills, CA 902111958
Telephone
310-432-8900Registry record last updated 25 Mar 2014.
Clinical trials
- ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer
Sponsor: Premiere Oncology
- Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Sponsor: Chap, Linnea I., M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
91 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202525 payments$34,440openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year202525 payments$14,268openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202533 payments$13,327openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
88.7%RANK Ligand Inhibitor88.5%Denosumab99%Prolia1%Xgeva0%Part D + Part B<11 patientsBisphosphonate0.2%Zoledronic Acid100%Part D<11 patientsCancer & immunology
8.4%Aromatase Inhibitor6.3%Letrozole48%Anastrozole27%Exemestane25%Part D≥36 patientsKinase inhibitor1.2%Kisqali58%Lapatinib22%Everolimus19%Part D<11 patients+ 4 more classes in this area
Nervous system
1.8%Gabapentinoids1.2%Gabapentin81%Pregabalin19%Part D<11 patientsSNRI0.3%Duloxetine Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–2001 per NIH RePORTER. The latest:
- INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR
University of California Los Angeles
FY2001$207,266M01RR000865 - INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR
University of California Los Angeles
FY2001$207,266M01RR000865 - INTRAPERITONEAL IL 2 FOR EPITHELIAL OVARIAN CANCER W/ PATHOLOGICAL CR
University of California Los Angeles
FY1999M01RR000865
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant <scp>GEICAM</scp> Spanish Breast Cancer Group and <scp>TRIO</scp> Translational Research in Oncology Group studies
International Journal of Cancer
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Beth Karlan, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Jerome Engel, MD
University of California, Los Angeles
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”